OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Expert opinion on Real World Evidence RWE in drug development and usage
N. Martini, G. Trifirò, A. Capuano, et al.
(2020) Vol. 02, Iss. 02
Open Access | Times Cited: 13
N. Martini, G. Trifirò, A. Capuano, et al.
(2020) Vol. 02, Iss. 02
Open Access | Times Cited: 13
Showing 13 citing articles:
Real-World Safety Data of the Orphan Drug Onasemnogene Abeparvovec (Zolgensma®) for the SMA Rare Disease: A Pharmacovigilance Study Based on the EMA Adverse Event Reporting System
Rosanna Ruggiero, Nunzia Balzano, Maria Maddalena Nicoletti, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 394-394
Open Access | Times Cited: 5
Rosanna Ruggiero, Nunzia Balzano, Maria Maddalena Nicoletti, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 394-394
Open Access | Times Cited: 5
Real-World Evidence to Reinforce Clinical Trial Evidence in Health Technology Assessment: A Critical Review of Real-World Evidence Requirements from Seven Countries and Recommendations to Improve Acceptance
K. Thokagevistk, Céline Coppo, L Rey, et al.
Journal of Market Access & Health Policy (2024) Vol. 12, Iss. 2, pp. 105-117
Open Access | Times Cited: 2
K. Thokagevistk, Céline Coppo, L Rey, et al.
Journal of Market Access & Health Policy (2024) Vol. 12, Iss. 2, pp. 105-117
Open Access | Times Cited: 2
EA3: A softmax algorithm for evidence appraisal aggregation
Francesco De Pretis, Jürgen Landes
PLoS ONE (2021) Vol. 16, Iss. 6, pp. e0253057-e0253057
Open Access | Times Cited: 7
Francesco De Pretis, Jürgen Landes
PLoS ONE (2021) Vol. 16, Iss. 6, pp. e0253057-e0253057
Open Access | Times Cited: 7
PRICING FOR MULTI INDICATION MEDICINES: A DISCUSSION WITH ITALIAN EXPERTS
Luca Pani, A. Cicchetti, A. De Luca, et al.
(2022), Iss. online first
Open Access | Times Cited: 5
Luca Pani, A. Cicchetti, A. De Luca, et al.
(2022), Iss. online first
Open Access | Times Cited: 5
PRICING FOR MULTI INDICATION MEDICINES: A DISCUSSION WITH ITALIAN EXPERTS
L. Pani, A. Cicchetti, A. De Luca, et al.
(2022), Iss. online first
Open Access | Times Cited: 5
L. Pani, A. Cicchetti, A. De Luca, et al.
(2022), Iss. online first
Open Access | Times Cited: 5
The Importance of Real-World Evidence in Understanding Influenza Vaccine Effectiveness
Pietro Ferrara, LG Mantovani
Farmeconomia Health economics and therapeutic pathways (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Pietro Ferrara, LG Mantovani
Farmeconomia Health economics and therapeutic pathways (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 4
A methodology to assess the population size and estimate the needed resources for new licensed medications by combining clinical and administrative databases: The example of glycated haemoglobin in type 2 diabetes
Francesco Lapi, Elisa Bianchini, Ettore Marconi, et al.
Pharmacoepidemiology and Drug Safety (2023) Vol. 32, Iss. 10, pp. 1083-1092
Closed Access | Times Cited: 2
Francesco Lapi, Elisa Bianchini, Ettore Marconi, et al.
Pharmacoepidemiology and Drug Safety (2023) Vol. 32, Iss. 10, pp. 1083-1092
Closed Access | Times Cited: 2
ARTIFICIAL INTELLIGENCE AND PHARMACOLOGISTS:THREAT OR OPPORTUNITY?
Francesco Visioli
(2023) Vol. 05, Iss. 01, pp. 02-02
Open Access | Times Cited: 1
Francesco Visioli
(2023) Vol. 05, Iss. 01, pp. 02-02
Open Access | Times Cited: 1
Survival and Recurrence Patterns in Patients With Stomach Adenocarcinoma Receiving Chemotherapy or Chemoradiotherapy After D2 Gastrectomy in a Tertiary Care Cancer Institute: A Retrospective Real-World Evidence Cohort Study
Swarupa Mitra, David K. Simson, Manish Gehani, et al.
Advances in Radiation Oncology (2023) Vol. 8, Iss. 6, pp. 101280-101280
Open Access | Times Cited: 1
Swarupa Mitra, David K. Simson, Manish Gehani, et al.
Advances in Radiation Oncology (2023) Vol. 8, Iss. 6, pp. 101280-101280
Open Access | Times Cited: 1
Two years clinical outcomes of patients treated with EucaLimus Sirolimus Eluting Stents. A Real World Experience
Maurizio Viecca, Vincenzo Vizzi, Giuseppe Alessandrino, et al.
(2021) Vol. 4, Iss. 1, pp. 56-56
Open Access | Times Cited: 1
Maurizio Viecca, Vincenzo Vizzi, Giuseppe Alessandrino, et al.
(2021) Vol. 4, Iss. 1, pp. 56-56
Open Access | Times Cited: 1
Real-world evidence: What is it and why does it matter to pharmacists?
Usman Abubakar Haruna, Shuaibu Saidu Musa, Emery Manirambona, et al.
Clinical Epidemiology and Global Health (2023) Vol. 20, pp. 101229-101229
Open Access
Usman Abubakar Haruna, Shuaibu Saidu Musa, Emery Manirambona, et al.
Clinical Epidemiology and Global Health (2023) Vol. 20, pp. 101229-101229
Open Access
Therapeutic drug monitoring for the cancer patient: challenges and opportunities
Sabrina Angelini, Erika Cecchin, Valeria Conti, et al.
(2021) Vol. 3, Iss. 3, pp. 591-591
Open Access
Sabrina Angelini, Erika Cecchin, Valeria Conti, et al.
(2021) Vol. 3, Iss. 3, pp. 591-591
Open Access
Pharmacovigilance, drug interactions, pharmacogenetics and therapeutic drug monitoring of anticancer agents: a valuable support for clinical practice
Emanuel Raschi, Marzia Del Re, Valentino Conti, et al.
(2021) Vol. 3, Iss. 3, pp. 550-550
Open Access
Emanuel Raschi, Marzia Del Re, Valentino Conti, et al.
(2021) Vol. 3, Iss. 3, pp. 550-550
Open Access
